Statera BioPharma Return on Equity

Statera BioPharma (STAB) currently reports a ROE of 1018.79%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Statera BioPharma's ROE history and peer comparisons.

Statera BioPharma's ROE of 1018.79% is higher than the Healthcare sector average of 21.67%. That is roughly 4601.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Statera BioPharma's current 1018.79% should be judged against Healthcare norms (sector average: 21.67%) and against STAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1018.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Statera BioPharma, and consider following STAB for alerts when major investors trade the stock.

Statera BioPharma is classified in the Healthcare sector. On ROE, it currently shows 1018.79% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STAB with unrelated industries.